Nurse Says CAR-T Cell Therapy is a ‘Mind-Blowing’ Advancement


For patients with blood cancers, CAR-T cell therapy has been a “mind-blowing” advancement for treatment in the cancer space.

In the ever-advancing cancer space, more types of treatments have been available, notably CAR-T cell therapy.

“When I first started my career, we were giving a lot of chemotherapy [and] a lot of bone marrow transplants,” Lauren Yakelis said during an interview.

Yakelis is an oncology nurse at Ochsner Medical Center in New Orleans and was a 2024 Extraordinary Healer finalist. She noted that now, new treatments have “evolved” in the cancer space, including CAR-T cell therapy.

“That's mind-blowing to me that your own body is now fighting the cancer cells and reproducing and killing the cancer,” she said.

READ MORE: Blood Cancer Expert Talks CAR-T Cell Therapy Risks, Benefits

CAR-T cell therapy typically treats patients with certain blood cancers, the National Cancer Institute explains. For patients eligible for CAR-T cell therapy, doctors take T-cells from patients’ blood. They then add a specific gene that binds to a certain protein on the cancer cells to destroy them. After many CAR T cells have grown, patients receive the therapy via an infusion.

In early April 2024, the Food and Drug Administration approved Carvykti (ciltacabtageneautoleucel; cilta-cel) for certain patients with relapsed or refractory multiple myeloma. The approval came following results from the phase 3 CARTITUDE-4 trial.

Yakelis sat down with CURE® at the 2024 Extraordinary Healer® Award event and discussed the advances in cancer treatment during her career.


Just recently is when I realized this is why I chose oncology. When I first started my career, we were giving a lot of chemotherapy, a lot of bone marrow transplants, which are cool. But and I knew that in the next 40 to 50 years in my career, I would see all the new treatments that evolved in cancer therapy. So now CAR-T cell therapy is something I've never seen where you take your own T-cells in your body, your own immune system and you engineer those cells to go fight the cancer.

That's mind-blowing to me that your own body is now fighting the cancer cells and reproducing and killing the cancer. Patients are 30 days on the line after we do their first scan and they're in remission. It's mind-blowing, so to see where we've come, this is why I chose oncology because I just want to help people regain their life and their quality of life and live longer with their families.

Transcript has been edited for clarity and conciseness.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.

Related Videos
Image of Kathy Mooney
Jessica McDade, B.S.N., RN, OCN, in an interview with CURE
For patients with cancer, the ongoing chemotherapy shortage may cause some anxiety as they wonder how they will receive their drugs. However, measuring drugs “down to the minutiae of the milligrams” helped patients receive the drugs they needed, said Alison Tray. Tray is an advanced oncology certified nurse practitioner and current vice president of ambulatory operations at Rutgers Cancer Institute in New Jersey.  If patients are concerned about getting their cancer drugs, Tray noted that having “an open conversation” between patients and providers is key.  “As a provider and a nurse myself, having that conversation, that reassurance and sharing the information is a two-way conversation,” she said. “So just knowing that we're taking care of you, we're going to make sure that you receive the care that you need is the key takeaway.” In June 2023, many patients were unable to receive certain chemotherapy drugs, such as carboplatin and cisplatin because of an ongoing shortage. By October 2023, experts saw an improvement, although the “ongoing crisis” remained.  READ MORE: Patients With Lung Cancer Face Unmet Needs During Drug Shortages “We’re really proud of the work that we could do and achieve that through a critical drug shortage,” Tray said. “None of our patients missed a dose of chemotherapy and we were able to provide that for them.” Tray sat down with CURE® during the 49th Annual Oncology Nursing Society Annual Congress to discuss the ongoing chemo shortage and how patients and care teams approached these challenges. Transcript: Particularly at Hartford HealthCare, when we established this infrastructure, our goal was to make sure that every patient would get the treatment that they need and require, utilizing the data that we have from ASCO guidelines to ensure that we're getting the optimal high-quality standard of care in a timely fashion that we didn't have to delay therapies. So, we were able to do that by going down to the minutiae of the milligrams on hand, particularly when we had a lot of critical drug shortages. So it was really creating that process to really ensure that every patient would get the treatment that they needed. For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.
Image of a woman with dark brown hair and round glasses wearing pearl earrings.
Woman with dark brown hair and pink lipstick wearing a light pink blouse with a light brown blazer. Patients should have conversations with their providers about treatments after receiving diagnoses.
Man in a navy suit with a purple tie. Dr. Saby George talks to CURE about how treatment with Opdivo could mitigate disparities in patients with kidney cancer.
Dr. Andrea Apolo in an interview with CURE
Related Content